EXTON, Pa., Oct. 29 ViroPharma Incorporated (Nasdaq: VPHM) today announced that the company will be presenting at several upcoming healthcare investment conferences.
Advertisement
Vincent Milano, president and chief executive officer of ViroPharma, will present at the Oppenheimer 20th Annual Healthcare Conference at 4:30 P.M. EST on Tuesday, November 3, 2009. The conference is being held at the Waldorf=Astoria in New York City.
Advertisement
Charles Rowland, vice president and chief financial officer of ViroPharma, will present at the Credit Suisse 2009 Healthcare Conference at 12:00 P.M. MST on Wednesday, November 11, 2009. The conference is being held at the Arizona Biltmore Hotel in Phoenix, AZ.
William Roberts, vice president, corporate communications will present at the Lazard Capital Markets 6th Annual Healthcare Conference at 2:45 P.M. EST on Wednesday, November 18, 2009. The conference is being held at the St. Regis Hotel in New York City.
ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin®, approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. ViroPharma commercializes Cinryze(TM) (C1 esterase inhibitor (human)) for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema (HAE), also known as C1 inhibitor deficiency (for prescribing information on ViroPharma's commercial products, please download the package inserts at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses its drug development activities in diseases including cytomegalovirus (CMV), HAE and C. difficile.
ViroPharma routinely posts information, including press releases, which may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.
SOURCE ViroPharma Incorporated
